Silexion Seeks 500M Share Authorization and 1-for-15 to 1-for-25 Reverse Split to Avoid Nasdaq Delisting
SLXN is trading near its 52-week low of $0.236 (10% above the low) on light trading volume (0.2× avg).
Summary
Silexion Therapeutics is seeking shareholder approval for a 500 million share authorization increase and a 1-for-15 to 1-for-25 reverse split to regain Nasdaq compliance after receiving a delisting notice for its sub-$1.00 share price.
Updates
· SEC 8-K — Nasdaq staff determined the bid price deficiency on September 25, 2026, and the hearings panel will consider it in deciding whether Silexion remains listed.
Key Events · Corporate Governance and Compliance · SLXN
-
500M Share Authorization Increase Proposed
Proposal 1 seeks to increase authorized ordinary shares from 15.9 million to 515.9 million — a 3,145% increase — to fund operations and restore Nasdaq equity compliance.
-
Reverse Split of 1-for-15 to 1-for-25
Proposal 2 authorizes the board to effect a reverse split at a ratio between 1-for-15 and 1-for-25 to lift the share price above Nasdaq's $1.00 minimum bid requirement.
-
Nasdaq Delisting Notice Received
Silexion received a listing deficiency notice on September 25, 2026 after its closing bid price stayed below $1.00 for 30 consecutive trading days; a hearings panel appearance occurred September 24, 2026.
-
Shareholders' Equity Below Nasdaq Minimum
Shareholders' equity was approximately $2.477 million as of September 24, 2026, just below the $2.5 million Nasdaq Capital Market equity standard.
Analysis · SLXN · Life Sciences
Silexion is asking shareholders to approve a massive 500 million share authorization increase — up from the 175 million requested in August — alongside a reverse split of 1-for-15 to 1-for-25. The company received a Nasdaq delisting notice on September 25, 2026 for failing the $1.00 minimum bid price rule, and its shareholders' equity of approximately $2.477 million remains just below the $2.5 million Nasdaq minimum. The authorization increase alone would expand authorized shares by 3,145%, and the company states it has zero remaining authorized but unissued shares available. This is a survival filing: without approval, Silexion faces delisting and an inability to fund its Phase 2/3 SIL204 pancreatic cancer trial.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 45% of the 300 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.24 to $42.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.